Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study

Rituximab causes hepatitis B virus (HBV) reactivation in HBV surface antigen (HBsAg)-seronegative patients with CD20-positive B-cell non-Hodgkin lymphoma (CD20(+) NHL), especially for those seropositive to the antibody of core antigen (anti-HBc). Clinical hepatitis usually develops after reverse ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsiao, Liang-Tsai, Chiou, Tzeon-Jye, Gau, Jyh-Pyng, Yang, Ching-Fen, Yu, Yuan-Bin, Liu, Chun-Yu, Liu, Jin-Hwang, Chen, Po-Min, Tzeng, Cheng-Hwai, Chan, Yu-Jiun, Yang, Muh-Hwa, Huang, Yi-Hsiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616669/
https://www.ncbi.nlm.nih.gov/pubmed/26266374
http://dx.doi.org/10.1097/MD.0000000000001321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616669/
https://www.ncbi.nlm.nih.gov/pubmed/26266374
http://dx.doi.org/10.1097/MD.0000000000001321

Ejemplares similares